Press release
Human Papillomavirus Associated Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Human Papillomavirus Associated Cancer pipeline constitutes key companies continuously working towards developing Human Papillomavirus Associated Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Human Papillomavirus Associated Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Human Papillomavirus Associated Cancer Market.
The Human Papillomavirus Associated Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Human Papillomavirus Associated Cancer Pipeline Report: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Human Papillomavirus Associated Cancer treatment therapies with a considerable amount of success over the years. Human Papillomavirus Associated Cancer Key players such as - Nutcracker Therapeutics, Vaccitech, ISA Pharmaceutical, Transgene, Hookipa Biotech GmbH, SQZ Biotechnologies, Turnstone Biologics, ISA Pharmaceuticals, Nykode Therapeutics, BioNTech SE, PDS Biotechnology Corp., and others, are developing therapies for the Human Papillomavirus Associated Cancer treatment
• Human Papillomavirus Associated Cancer Emerging therapies such as - NTX 250, VTP 1100, ISA 201, TG4001, HB-201, SQZ-eAPC-HPV, TBio-6517, ISA 101, VB10.16, BNT113, PDS0101, and others are expected to have a significant impact on the Human Papillomavirus Associated Cancer market in the coming years.
• In March 2025, Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that a patient with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) has been dosed in ACESOT-1051, a Phase 1 clinical trial investigating APR-1051 in advanced solid tumors with cancer-related genetic alterations. According to the National Cancer Institute, APR-1051 is an oral inhibitor of the WEE1 protein kinase, which is often overexpressed in various cancers and linked to poor clinical outcomes. By inhibiting WEE1, APR-1051 aims to trigger premature cell division, disrupt the cell cycle, and accumulate unrepaired DNA damage, ultimately leading to the destruction of vulnerable tumor cells.
• In March 2025, Cytotoxic chemotherapy remains the standard treatment for patients with unresectable or metastatic squamous cell carcinoma of the anal canal-a rare form of anal cancer commonly associated with human papillomavirus (HPV) infection. However, this approach offers limited effectiveness and is often linked to poor patient outcomes. To explore more effective options, a research team led by Van Morris, M.D., conducted a Phase II clinical trial assessing the combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF antibody bevacizumab in 20 patients with unresectable and/or metastatic HPV-related anal cancer.
Human Papillomavirus Associated Cancer Overview
Human Papillomavirus (HPV)-Associated Cancer refers to cancers caused by infection with certain types of HPV, a common sexually transmitted virus. Persistent infection with high-risk HPV strains can lead to cellular changes and the development of cancers, most commonly cervical cancer. HPV is also linked to other cancers, including anal, oropharyngeal (throat), vulvar, and vaginal cancers. Vaccination, regular screening, and early detection are key strategies to prevent and manage HPV-associated cancers.
Get a Free Sample PDF Report to know more about Human Papillomavirus Associated Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Human Papillomavirus Associated Cancer Drugs Under Different Phases of Clinical Development Include:
• NTX 250: Nutcracker Therapeutics
• VTP 1100: Vaccitech
• STP909: Sirnaomics Inc
• RTX-321: Rubius Therapeutics
• BVAC-C: Cellid Co Ltd.
• GX-188E: Genexine Inc
• ITI-2000: Immunomic Therapeutics Inc
• ISA 201 :ISA Pharmaceutical
• TG4001: Transgene
• HB-201: Hookipa Biotech GmbH
• SQZ-eAPC-HPV: SQZ Biotechnologies
• TBio-6517: Turnstone Biologics
• ISA 101: ISA Pharmaceuticals
• VB10.16: Nykode Therapeutics
• BNT113: BioNTech SE
• PDS0101: PDS Biotechnology Corp.
Route of Administration
Human Papillomavirus Associated Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
• Small molecule
• Gene Therapy
• Cell Therapy
• Immunotherapy
Human Papillomavirus Associated Cancer Pipeline Therapeutics Assessment
• Human Papillomavirus Associated Cancer Assessment by Product Type
• Human Papillomavirus Associated Cancer By Stage and Product Type
• Human Papillomavirus Associated Cancer Assessment by Route of Administration
• Human Papillomavirus Associated Cancer By Stage and Route of Administration
• Human Papillomavirus Associated Cancer Assessment by Molecule Type
• Human Papillomavirus Associated Cancer by Stage and Molecule Type
DelveInsight's Human Papillomavirus Associated Cancer Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Human Papillomavirus Associated Cancer Therapeutics Market include:
Some of the key companies developing therapies for the HPV Associated Cancer treatment are - Beijing Kangleweishi Biotechnology Co Ltd, Genexine Inc, Merck KGaA, Apimeds Inc, AstraZeneca Plc, Bristol-Myers Squibb Co, eTheRNA Immunotherapies NV, Hookipa Pharma Inc, ISA Pharmaceuticals BV, and Theravectys SA, and others.
Human Papillomavirus Associated Cancer Pipeline Analysis:
The Human Papillomavirus Associated Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Human Papillomavirus Associated Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Human Papillomavirus Associated Cancer Treatment.
• Human Papillomavirus Associated Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Human Papillomavirus Associated Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Human Papillomavirus Associated Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Human Papillomavirus Associated Cancer product details are provided in the report. Download the Human Papillomavirus Associated Cancer pipeline report to learn more about the emerging Human Papillomavirus Associated Cancer therapies
https://www.delveinsight.com/report-store/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Human Papillomavirus Associated Cancer Pipeline Market Drivers
• Increase in prevalence of Human Papillomavirus Hpv Associated Cancer
• Increase in Research and Development
Human Papillomavirus Associated Cancer Pipeline Market Barriers
• Lack of in-depth understanding of the disease pathogenesis
• High cost associated with the treatment
Scope of Human Papillomavirus Associated Cancer Pipeline Drug Insight
• Coverage: Global
• Key Human Papillomavirus Associated Cancer Companies: Nutcracker Therapeutics, Vaccitech, ISA Pharmaceutical, Transgene, Hookipa Biotech GmbH, SQZ Biotechnologies, Turnstone Biologics, ISA Pharmaceuticals, Nykode Therapeutics, BioNTech SE, PDS Biotechnology Corp., and others
• Key Human Papillomavirus Associated Cancer Therapies: NTX 250, VTP 1100, ISA 201, TG4001, HB-201, SQZ-eAPC-HPV, TBio-6517, ISA 101, VB10.16, BNT113, PDS0101, and others
• Human Papillomavirus Associated Cancer Therapeutic Assessment: Human Papillomavirus Associated Cancer current marketed and Human Papillomavirus Associated Cancer emerging therapies
• Human Papillomavirus Associated Cancer Market Dynamics: Human Papillomavirus Associated Cancer market drivers and Human Papillomavirus Associated Cancer market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Papillomavirus Associated Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight here
News-ID: 4216051 • Views: …
More Releases from DelveInsight Business Research

Insulin Resistance Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Insulin Resistance pipeline constitutes 8+ key companies continuously working towards developing 10+ Insulin Resistance treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Insulin Resistance Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Insulin Resistance Market.
The Insulin…

Hepatocellular Carcinoma Market Growth to Surge During Forecast Period (2024-203 …
DelveInsight's "Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hepatocellular Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatocellular Carcinoma Market Forecast
https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…

High-Grade Glioma Pipeline 2025: Therapies Under Investigation, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, High-Grade Glioma pipeline constitutes 150+ key companies continuously working towards developing 150+ High-Grade Glioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The High-Grade Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers…

Global Injectable Drug Delivery Devices Market to grow at a CAGR of 6.12% by 203 …
According to DelveInsight's analysis, The intraocular lens market is witnessing significant growth due to the rising prevalence of eye disorders such as cataracts, presbyopia, and astigmatism, which are driving demand for corrective surgeries. This trend is supported by greater awareness and improved access to eye care services, particularly in developing regions, allowing more patients to pursue treatment. Advances in lens materials and designs-including multifocal, toric, and extended depth-of-focus lenses-are improving…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…